Melissa G. Brammer

Oncology
1 Dna Way
South San Francisco, CA 94080

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.

Journal: Cancer causes & control : CCC
Published: January 22, 2016

Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.

Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.

Journal: The breast journal
Published: February 07, 2015

In response to L.N. Newcomer et al.

In response to L.N. Newcomer et al.

Journal: Journal of oncology practice
Published: December 18, 2014

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.

Journal: The oncologist
Published: August 03, 2014

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.

Journal: SpringerPlus
Published: May 14, 2014

Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

Journal: Journal of managed care & specialty pharmacy
Published: April 26, 2014

Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.

Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: April 18, 2014

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: April 16, 2014

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.

Journal: SpringerPlus
Published: February 14, 2014

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.

Journal: Cancer
Published: September 23, 2013

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

Journal: Cancer
Published: February 13, 2013

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.

Journal: Cancer chemotherapy and pharmacology
Published: January 25, 2013
Showing 1-12 of 13

Last Updated: 09/26/2026